Sanofi Ventures
Sanofi Ventures operates as the corporate venture capital arm of Sanofi.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sanofi Ventures Information
Geographic Data
Address: 50 Binney Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
6,601,935Website Global Rank
818Website Monthly Traffic
Twitter Followers
Description
Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2022 | Nucleai | Series B | 0 |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 7/2018 | Imbria Pharmaceuticals | Seed Round | - |
| 2/2023 | Avilar Therapeutics | Seed Round | 0 |
| 10/2019 | Icosavax | Series A | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 4/2018 | Common Sensing | Series A | 0 |
| 11/2017 | Inozyme | Series A | 49M |
| 7/2020 | Kalobios Pharmaceuticals, Inc. | Seed Round | - |
| 4/2017 | Evidation Health | Venture Round | 10M |
| 3/2010 | Bluebird Bio | Series B | 35M |
| 11/2022 | Escient Pharmaceuticals | Series C | 120M |
| 11/2018 | Kymera Therapeutics | Series B | 65M |
| 4/2020 | i2o Therapeutics | Seed Round | 4M |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 5/2021 | Therini Bio | Seed Round | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 4/2019 | Inozyme | Series A | 67.4M |
| 5/2020 | Q32 Bio | Series A | 46M |
| 7/2013 | Edimer | Series B | 18M |
| 10/2020 | Q32 Bio | Series B | 60M |
| 10/2013 | Immune Design | Series C | 49M |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 10/2018 | Click Therapeutics | Series A | 19M |
| 8/2022 | Empatica | Series B | 25.9M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 9/2013 | KAHR medical | Series A | 2.5M |
| 6/2019 | Omada Health | Series D | 73M |
| 10/2016 | Science 37 | Series B | 31M |
| 10/2022 | Normunity | Series A | 65M |
| 8/2018 | Evidation Health | Series C | 30M |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 12/2007 | NGI | Series A | 11.8M |
| 2/2016 | Yumanity Therapeutics | Series A | 51M |
| 10/2014 | Cogent Biosciences | Series A | 12.3M |
| 5/2013 | Lumena Pharmaceuticals | Series A | 23M |
| 7/2017 | NeuroVia | Series A | 14M |
| 2/2015 | Lysosomal Therapeutics | Series A | 20M |
| 5/2014 | Lysosomal Therapeutics | Seed Round | 4.8M |
| 6/2021 | Glycomine | Series B | 0 |
| 2/2019 | Aetion | Series B | 0 |
| 6/2017 | Omada Health | Series C | 50M |
| 4/2023 | Therini Bio | Series A | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 10/2021 | Click Therapeutics | Series B | 0 |
| 9/2019 | Veralox Therapeutics | Seed Round | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 1/2021 | Abcuro | Series A | 42M |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 11/2009 | Fate Therapeutics | Series B | 30M |
| 9/2015 | Selecta Biosciences | Series E | 38M |
| 4/2017 | Science 37 | Series C | 35M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 8/2020 | Science 37 | Venture Round | 0 |
| 12/2015 | Navitor Pharmaceuticals | Series B | 33M |
| 4/2021 | Icosavax | Series B | 0 |
| 12/2017 | Curisium | Seed Round | 3.5M |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 6/2020 | NodThera | Series B | 55M |
| 4/2022 | OMass Technologies | Series B | 0 |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 2/2021 | Medisafe | Series C | 0 |
| 12/2020 | Minervax | Series B | 57.6M |
| 12/2022 | Minervax | Series C | 0 |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 3/2016 | ImmuneXcite | Series A | 8.6M |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 4/2022 | OMass Technologies | Series B | 0 |
| 3/2022 | Nucleai | Series B | 0 |
| 10/2021 | Click Therapeutics | Series B | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 6/2021 | Glycomine | Series B | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
